Richard Staines discusses what has become one of the worst deals in pharma’s history – AbbVie’s purchase of Stemcentrx and its lung cancer drug Rova-T.
The life sciences services company Indegene has agreed to acquire a majority stake in the UK-based consulting company DT Associates, which focuses on areas such as customer experience and d
